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ABSTRACT: Azetidines are important motifs in medicinal chem-
istry, but there are a limited number of methods for their synthesis. 
Herein, we present a new method for their modular construction by 
exploiting the high ring strain associated with azabicyclo[1.1.0]bu-
tane. Generation of azabicyclo[1.1.0]butyl lithium followed by its 
trapping with a boronic ester gives an intermediate boronate com-
plex which, upon N-protonation with acetic acid, undergoes 1,2-mi-
gration with cleavage of the central C–N bond to relieve ring strain. 
The methodology is applicable to primary, secondary, tertiary, aryl 
and alkenyl boronic esters, and occurs with complete stereospeci-
ficity. The homologated azetidinyl boronic esters can be further 
functionalized through reaction of the N−H azetidine, and through 
transformation of the boronic ester. The methodology was applied 
to a short, stereoselective synthesis of the azetidine-containing 
pharmaceutical, cobimetinib. 
Nitrogen-containing heterocycles are the most prevalent and im-
portant heterocycles in medicinal chemistry, as evidenced by their 
presence in approximately 60% of U.S. FDA approved small-mol-
ecule drugs.1 Among this class of compounds, the saturated heter-
ocycles piperidine and pyrrolidine are some of the most commonly 
encountered. However, their four-membered ring analogue, azet-
idine,2 is much less prevalent, despite possessing a range of desira-
ble characteristics; its small, strained ring structure confers struc-
tural rigidity and fewer rotatable bonds, which has been shown to 
correlate with increased bioavailability,3 and they have been 
demonstrated to exhibit greater metabolic stability and improved 
physicochemical properties relative to their larger ring analogues.4 
Indeed, the azetidine moiety is featured in several pharmaceuticals, 
including cobimetinib (1),5 azelnipidine (2)6 and baricitinib (3)7 
(Figure 1A), as well as in biologically-active natural products.8 
However, despite these attractive features, there is a dearth of meth-
ods available to prepare azetidines.2,9 Some current methods in-
clude inter- and intramolecular alkylation of amine nucleophiles, 
reduction of -lactams,2 and the aza Paternò-Büchi reaction.10 
Therefore, the development of new methodologies that facilitate 
the modular synthesis of azetidines from common building blocks 
would be highly attractive, particularly in advancing medicinal 
chemistry programs.11 Herein, we describe a method to homologate 
readily available boronic esters with azabicyclo[1.1.0]butyl lithium 
(a novel species) to form versatile borylated azetidines, which can 
then be diversified through transformation of the amine and boronic 
ester functional groups.12  
Figure 1. (A) Selected azetidine-containing pharmaceuticals. 
(B) Strain-release 1,2-metalate rearrangement of bicyclo[1.1.0]bu-
tyl boronate complexes. (C) This work: strain-release 1,2-metalate 
rearrangement of azabicyclo[1.1.0]butyl boronate complexes. 
We recently reported the homologation of boronic esters by a cy-
clobutane unit by using bicyclo[1.1.0]butyl lithium (Figure 1B).13 
It was shown that bicyclo[1.1.0]butyl lithium could react with bo-
ronic esters to form highly strained bicyclo[1.1.0]butyl boronate 
complexes, which then underwent 1,2-metalate rearrangement 
upon treatment with electrophilic palladium(II)-aryl complexes to 
ultimately form a range of diastereomerically pure borylated cyclo-
butanes. The 1,2-metalate rearrangement is driven by relief of the 
high ring strain of the bi-cycle. We reasoned that the power inher-
ent in the relief of ring strain could be harnessed to drive 1,2-met-
alate rearrangements in other related ring systems.14 In particular, 
we were interested in the use of nitrogen-containing analogues of 
bicyclo[1.1.0]butyl lithium, such as azabicyclo[1.1.0]butyl lithium 
(4), since this would potentially enable the homologation of bo-
ronic esters to give synthetically- and pharmaceutically-important 
azetidines bearing a versatile boronic ester moiety (Figure 1C). 
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However, such a nucleophilic species (azabicyclo[1.1.0]butyl lith-
ium, 4) has not been previously reported. Reactions involving the 
parent azabicyclo[1.1.0]butane (5) are dominated by nucleophilic 
ring opening, which break the strained central C−N bond.15 
Scheme 1. (A) Lithiation of azabicyclo[1.1.0]butane and its 
trapping to form a sulfoxide. (B) Reaction optimization. 
 
a NMR yield. b Followed by Boc protection. c Isolated yield. 
d Gram-scale (4.76 mmol). 
In order to form azabicyclo[1.1.0]butyl lithium, we reasoned that 
the C−H bond at the bridgehead of 5 would be the most acidic, since 
it has the greatest s-character, and so could be selectively lithi-
ated.16 However, this route raised significant concerns since the 
strongly nucleophilic species, azabicyclo[1.1.0]butyl lithium, 
could potentially react with 5 to trigger a polymerization reac-
tion.15a,n To this end, it was discovered that azabicylo[1.1.0]butane, 
generated in situ from ammonium salt 6 by treatment with phenyl 
lithium at −78 °C,15l could be lithiated using s-butyl lith-
ium/TMEDA at −78 °C17 to form azabicyclo[1.1.0]butyl lithium 
(4). We elected to trap 4 as a sulfoxide, since this would potentially 
offer a stable, solid reagent from which 4 could be conveniently 
regenerated.13 Therefore, 4 was trapped with methyl 4-methylben-
zenesulfinate (7) to give azabicyclo[1.1.0]butyl sulfoxide 8 in 62% 
yield (Scheme 1A). Sulfoxide 8 was formed as a single regioiso-
mer, showing that selective deprotonation had indeed occurred, and 
problems relating to polymerization did not materialize, presuma-
bly due to a fast, low temperature lithiation step. The reaction was 
scalable and, as anticipated, 8 was a stable, easy-to-handle crystal-
line compound. 
With the azabicyclo[1.1.0]butyl sulfoxide 8 in hand, its conversion 
to azabicyclo[1.1.0]butyl lithium and subsequent reaction with 
cyclohexyl pinacol boronic ester 9 was investigated. Treatment of 
a mixture of 9 and 1.3 equivalents of 8 in 2-methyl tetrahydrofuran 
at −78 °C with 1.3 equivalents of tert-butyl lithium13 and then al-
lowing the reaction mixture to stir for two hours resulted in com-
plete boronate complex formation, as evidenced by a single peak at 
ca. 6 ppm in the 11B NMR spectrum of the reaction mixture. Sur-
prisingly, the boronate complex 10 did not undergo spontaneous 
1,2-metalate rearrangement, despite the high strain energy that 
would be released upon ring opening. We therefore needed to make 
the amine into a better leaving group18 and so explored different 
activating reagents.  Addition of benzyl chloroformate at low tem-
perature followed by warming did result in complete conversion of 
the boronate complex but gave an inseparable mixture of boronic 
and borinic esters 11 and 12, resulting from C-and O-migration re-
spectively, in a 1.5:1.0 ratio and a combined 92% NMR yield 
(Scheme 1B, entry 1). Benzoyl chloride behaved similarly (entry 
2). By contrast, we were pleased to find that simple protonation of 
the boronate complex with acetic acid resulted in exclusive C-mi-
gration and, following protection with a Boc group, azetidine 11 
was obtained in 78% NMR yield (Scheme 1B, entry 3). The added 
benefit of this approach is that it generates an unprotected N−H 
azetidine intermediate, which can then be reacted in any desired 
manner. Further improvements were achieved by switching the sol-
vent to THF and modifying the stoichiometry of the reagents 
(1.2 equivalents of 8 and tert-butyl lithium). The N−H azetidine 
products were easily separated from the sulfoxide by-product by 
filtering through a plug of silica gel: the azetidine acetic acid salt 
was retained on the silica and all other compounds eluted (‘silica 
catch’ method). The top layer of the silica gel plug was then col-
lected and subjected to Boc protection, giving pure 11 in 80% iso-
lated yield (1.39 g, 3.81 mmol, Scheme 1B, entry 4). It was also 
discovered that the reaction could be triggered using TsOH which 
enabled purification of the azetidine by precipitation of the tosylate 
salt without using the ‘silica catch’ purification (entry 5, see Sup-
porting Information for details). 
The robustness of these optimized conditions is illustrated by the 
preparation of over 25 unique azetidines (Scheme 2B). The scope 
of the boronic ester component was first explored and was found to 
encompass a broad range of primary, secondary and tertiary bo-
ronic esters. The range of primary boronic esters included n-alkyl 
(13), allylic (14), benzylic (15) and methyl (16), the latter being an 
important substituent in medicinal chemistry.19 The methyl group 
is normally a poor migrating group20 and so we were concerned that 
competing O-migration might occur, as had been observed when 
using benzyl chloroformate as an activating reagent. However, ex-
clusive C-migration was observed when using acetic acid as the ac-
tivator with this challenging substrate to give 16 in modest yield. 
Notable secondary boronic esters included an -amino boronic es-
ter,21 giving azetidine 23 featuring a piperidine substituent in 54% 
yield, and -alkoxy boronic ester, giving 3-oxypropylamine 24 in 
59% yield, both of which are motifs present in previously reported 
azetidine-containing pharmaceuticals.5,22 The tertiary boronic es-
ters included tert-butyl (27), adamantyl (28), substituted cyclobutyl 
(29),13 bicyclo[2.2.2]octyl (30),23 dimethyl phenyl silyl (31), and a 
doubly benzylic (32)24 boronic ester, giving the azetidine products 
in good to excellent yields. It was also possible to regioselectively 
homologate the primary boronic ester of a 1,2-bis(boronic ester),25 
giving 1,3-bis(boronic ester) 33, and perform a mono-homologa-
tion of a 1,1-bis(boronic ester),26 giving 1,2-bis(boronic ester) 34, 
in moderate yields. The enantiospecificity (e.s.)27 of the transfor-
mation was demonstrated using two enantioenriched boronic es-
ters, which gave products 18 and 32 with complete retention of ste-
reochemistry (100% e.s.). Furthermore, four diastereomerically 
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pure boronic esters were homologated to give the corresponding 
azetidine products, 20, 25, 26 and 29, with complete 
diastereospecificity (100% d.s.)28 Aryl and vinyl boronic esters 
could also be employed, giving the desired azetidines 35−38 in 
good yields.29
Scheme 2. Substrate scope of the azetidine homologation of boronic esters. (A) Optimized reaction conditions. (B) Boronic 
ester substrate scope. (C) Reaction performed without use of sulfoxide. 
 
All reactions were performed using 0.24 mmol of the boronic ester and all yields refer to isolated material. a NMR yield. PMP = para-
methoxyphenyl. e.s. (enantiospecificity) = [e.e. of product/e.e. of starting material] × 100%. d.s. (diastereospecificity) = [d.e. of product/d.e. 
of starting material] × 100%.
Finally, we explored whether the reaction could be achieved di-
rectly from the ammonium salt 6, thereby by-passing the sulfoxide 
intermediate 8, which could be more convenient when a single azet-
idine product is required. Thus, treatment of the ammonium salt 6 
with phenyl lithium, followed by sec-butyl lithium/TMEDA, cy-
clohexyl pinacol boronic ester, acetic acid and finally Boc protec-
tion, gave the homologated azetidine boronic ester product 11 in 
68% yield (Scheme 2C). 
We next demonstrated that a range of different transformations of 
the nitrogen atom of the intermediate N−H azetidine is possible 
(Figure 2A). In addition to the Boc protecting group, the nitrogen 
atom could also be protected with the tosyl (39) and Cbz (40) pro-
tecting groups in good yields. An amide coupling reaction with 
benzoic acid, using HATU as the coupling reagent, gave 41 also in 
good yield. A representative Buchwald−Hartwig cross-coupling30 
using 4-bromobenzonitrile gave aniline 42 in 71% yield. The inter-
mediate could also be engaged in SNAr reactions with a range of 
(hetero)aryl halides to give 44−49 in good yields. These reaction 
classes are among the most commonly used reactions within the 
field of medicinal chemistry.31 
To demonstrate the synthetic utility of the borylated azetidine prod-
ucts, azetidinyl boronic ester 11 was subjected to a range of repre-
sentative boronic ester transformations, including oxidation to the 
corresponding alcohol (48), vinylation (49),32 arylation to incorpo-
rate a pyridine (50)33 and formation of trifluoroborate salt 51 (Fig-
ure 2B).24 In all cases, good to excellent yields of the functionalized 
azetidines were achieved. Finally, a deboronative fluorination was 
performed,34 yielding fluorinated azetidine 52 in moderate yield. 
Fluorinated amines are important motifs since the fluorine atom can 
lead to beneficial modulation of the molecules’ physical and chem-
ical properties, including the pKa of the amine.35 
Finally, to showcase the application of this new method we targeted 
the preparation of cobimetinib (1), an MEK inhibitor used in the 
treatment of melanoma.5 Starting from ammonium salt 6, azabicy-
clo[1.1.]butyl lithium 4 was prepared by deprotonation (see 
Scheme 2C) and reacted with (R)-N-Boc piperidyl 2-pinacol bo-
ronic ester 5321,36 to give the N−H azetidine intermediate 54. 
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Subsequent in situ acylation of 54 with the required acid fluoride5 
delivered boronic ester 55 in 62% yield and with complete enanti-
ospecificity. Finally, oxidation with basic peroxide gave alcohol 56 
in 89% yield, and subsequent Boc deprotection gave cobimetinib 
(Scheme 3).5 This asymmetric synthesis of cobimetinib is shorter 
than previously reported routes,37 and provides a modularity that 
potentially enables facile preparation of analogues through use of 
different boronic esters, acid halides, and/or boronic ester transfor-
mations. 
In conclusion, we have developed a procedure that enables the 
modular construction of a diverse family of azetidines by the  
Figure 2. Synthetic transformations of borylated azetidines. (A) 
Alternative reactions at nitrogen. See Scheme 1A for conditions to 
form the acetic acid ammonium salt intermediate. Abbreviated re-
action conditions: a TsCl, Et3N; b benzyl chloroformate, Et3N; 
c PhCOOH, N,N-diisopropylethylamine, HATU; d Tosic acid salt 
used, Pd2(dba)3, Xantphos, 4-bromobenzonitrile, NaOtBu; e Ar-X 
(X = F or Cl), Et3N. (B) Boronic ester transformations using 11 as 
the substrate. Abbreviated reaction conditions: f H2O2/NaOH; g vi-
nyl lithium, then I2, then NaOMe; h ArLi, then 2,2,2-trichloroethyl 
chloroformate, then H2O2/NaOH; i KHF2; j trifluoroacetic acid, 
AgNO3, Selectfluor®, then Boc2O, Et3N. Cbz = carboxybenzyl. Ts 
= para-toluenesulfonyl. 
homologation of boronic esters with an azetidine unit. Key to suc-
cess was the generation of azabicyclo[1.1.0]butyl lithium either di-
rectly from the ammonium salt 6 or via the sulfoxide 4. This novel 
nucleophilic source of azabicyclo[1.1.0]butane is an unusual chem-
ical building block that is likely to find broader applications in syn-
thesis. 
Scheme 3. Modular synthesis of cobimetinib. 
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